Who are Bendamustine, Lenalidomide, Rituximab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bendamustine-lenalidomide-rituximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bendamustine, Lenalidomide, Rituximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bendamustine, Lenalidomide, Rituximab (Bendamustine, Lenalidomide, Rituximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy agent, Immunomodulator, Monoclonal antibody. Area: Oncology.

phase 2 Chemotherapy agent, Immunomodulator, Monoclonal antibody CD20, DNA replication Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bendamustine, Lenalidomide, Rituximab (Bendamustine, Lenalidomide, Rituximab) — Fondazione Italiana Linfomi - ETS. Bendamustine is a chemotherapy medication that works by interfering with DNA replication, Lenalidomide is an immunomodulatory drug that affects the immune system, Rituximab is a monoclonal antibody that targets CD20 on B cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bendamustine, Lenalidomide, Rituximab TARGET	Bendamustine, Lenalidomide, Rituximab	Fondazione Italiana Linfomi - ETS	phase 2	Chemotherapy agent, Immunomodulator, Monoclonal antibody	CD20, DNA replication

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy agent, Immunomodulator, Monoclonal antibody class)

Fondazione Italiana Linfomi - ETS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bendamustine, Lenalidomide, Rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/bendamustine-lenalidomide-rituximab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing